Gemfibrozil

Evidence Level: L4

Predicted Indications: 9

Gemfibrozil

Pharmacist Assessment Report

Gemfibrozil: From Hypertriglyceridemia to Rheumatoid Arthritis

One-Sentence Summary

Gemfibrozil is a PPAR-alpha agonist originally used to treat hypertriglyceridemia. The TxGNN model predicts it may be effective for rheumatoid arthritis, but the support so far consists only of animal and related-drug preclinical studies, with no registered clinical trials. Other predicted indications (HIV-associated lipid disorders and hypoalphalipoproteinemia) have considerably stronger evidence and are noted below.

Quick Overview

Item	Content
Original Indication	Hypertriglyceridemia
Predicted New Indication	Rheumatoid arthritis
TxGNN Prediction Score	0.9990
Evidence Level	L4
India Market Status	Listed in a compiled Indian medicine price dataset (8 of 8) – CDSCO approval status is not included in this data
Number of Listed Products	8 (valid: 8)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Gemfibrozil activates PPAR-alpha, a nuclear receptor that regulates fat metabolism. This is how it lowers triglycerides and raises HDL cholesterol. PPAR signalling also has anti-inflammatory and immune-modulating effects, including influence on T-cell and cytokine pathways. These are processes involved in rheumatoid arthritis. Detailed mechanism-of-action data were not available in the data compiled for this report, so this link rests on the known pharmacology of the drug class.

Direct evidence is thin. A rat study (2019) found that gemfibrozil combined with a reduced steroid dose gave a similar outcome to the full steroid dose in adjuvant-induced arthritis. A 2026 animal study with bezafibrate, a related pan-PPAR agonist, reported reduced experimental arthritis through PPAR-dependent pathways. Neither is human data, and the original lipid indication is only indirectly related to joint inflammation.

Clinical Trial Evidence

Currently no related clinical trials registered for rheumatoid arthritis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30074417	2019	Preclinical (rat model)	Modern Rheumatology	Gemfibrozil plus reduced-dose prednisolone gave a similar picture to full-dose steroid in adjuvant-induced arthritis
41207105	2026	Preclinical (related drug)	International Immunopharmacology	Bezafibrate, a pan-PPAR agonist, attenuated experimental arthritis via PPAR-dependent pathways
20083653	2010	Preclinical (mechanistic)	Journal of Immunology	Nitric oxide and Foxp3 regulation in T cells; background on immune mechanisms

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
168871	Oxipace 300mg Tablet	Strip of 10 tablets	Not specified
121328	Lopid Capsule	Strip of 10 capsules	Not specified
97053	Gempar 300mg Capsule	Strip of 10 capsules	Not specified
194412	Regulipid Tablet	Strip of 30 tablets	Not specified
221144	Triglyd 600mg Tablet	Strip of 10 tablets	Not specified

Eight valid single-ingredient registrations exist in total.

Safety Considerations

Contraindications (not from label text; the TxGNN model (deep learning) may reflect similarities it learned between related diseases, not biological evidence): liver disease, gallbladder disease, cholelithiasis and related biliary stone conditions, primary biliary cholangitis, impaired renal function, thrombocytopenia, leukopenia, anaemia (including macrocytic anaemia).
Drug Interactions: 129 interactions were identified. Major ones include:
- Statins: rosuvastatin and simvastatin
- Antidiabetic agents: pioglitazone and repaglinide
- Antidiarrhoeals: loperamide and eluxadoline
- Moderate interactions include insulins, nateglinide, rosiglitazone, chlorpropamide, tolazamide, rifaximin and chenodeoxycholic acid.

Please refer to the package insert for label warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The high TxGNN score is not backed by human evidence. There are no registered trials, and the literature is limited to animal studies and a related-drug study. The mechanistic link is plausible but unproven.

To proceed, the following is needed:

Controlled preclinical confirmation with gemfibrozil itself, and any early-phase human data in rheumatoid arthritis
Detailed mechanism-of-action data
Package insert warnings and contraindications from the Indian market
A drug-interaction plan, since rheumatoid arthritis patients commonly take multiple medications

Other Predicted Indications (Supplementary)

Rank	Predicted Indication	Score	Evidence Level	Decision	Notes
3	HIV infectious disease	0.9980	L2	Research Question	Supports managing protease-inhibitor-associated hypertriglyceridaemia, not treating HIV itself. Includes a randomized double-blind study (PMID 12409741) and a comparative effectiveness study (PMID 23892238). One Phase 1 trial (NCT00039663) was low relevance. Interaction risk with statins and antiretrovirals requires guardrails.
4	Hypoalphalipoproteinemia (low HDL)	0.9977	L3	Proceed with Guardrails	Several small, older crossover and comparison studies (1989–2000) showing lipoprotein changes. Mostly surrogate endpoints. No registered trials.
9	Sclerosing cholangitis	0.9970	L5	Hold	Literature covers fibrate safety in cholestatic disease, not efficacy. Hepatotoxicity concern.
2, 5, 6, 7, 10	Multiple endocrine neoplasia; brachydactyly-syndactyly syndrome; colobomatous microphthalmia-rhizomelic dysplasia syndrome; methemoglobinemia, alpha type; methemoglobin reductase deficiency	99.70–0.9983	L5	Hold	No clinical or literature evidence and no plausible mechanistic link. Computational prediction only.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.